229 related articles for article (PubMed ID: 17203008)
1. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications.
Kowal-Bielecka O; Kowal K; Distler O; Gay S
Nat Clin Pract Rheumatol; 2007 Jan; 3(1):43-51. PubMed ID: 17203008
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators.
Kowal-Bielecka O; Kowal K; Distler O; Rojewska J; Bodzenta-Lukaszyk A; Michel BA; Gay RE; Gay S; Sierakowski S
Arthritis Rheum; 2005 Dec; 52(12):3783-91. PubMed ID: 16320329
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
[TBL] [Abstract][Full Text] [Related]
4. Eicosanoids in asthma.
Wan KS; Wu WF
Acta Paediatr Taiwan; 2007; 48(6):299-304. PubMed ID: 18437962
[TBL] [Abstract][Full Text] [Related]
5. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
Charbeneau RP; Peters-Golden M
Clin Sci (Lond); 2005 Jun; 108(6):479-91. PubMed ID: 15896193
[TBL] [Abstract][Full Text] [Related]
6. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis.
Kowal-Bielecka O; Kowal K; Lewszuk A; Bodzenta-Lukaszyk A; Walecki J; Sierakowski S
Ann Rheum Dis; 2005 Mar; 64(3):484-6. PubMed ID: 15708900
[TBL] [Abstract][Full Text] [Related]
7. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution.
Serhan CN
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):141-62. PubMed ID: 16005201
[TBL] [Abstract][Full Text] [Related]
8. Formation and effects of leukotrienes and lipoxins in human bone marrow.
Lindgren JA; Stenke L; Mansour M; Edenius C; Laurén L; Näsman-Glaser B; Ericsson I; Reizenstein P
J Lipid Mediat; 1993; 6(1-3):313-20. PubMed ID: 8357990
[TBL] [Abstract][Full Text] [Related]
9. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.
Chiang N; Serhan CN; Dahlén SE; Drazen JM; Hay DW; Rovati GE; Shimizu T; Yokomizo T; Brink C
Pharmacol Rev; 2006 Sep; 58(3):463-87. PubMed ID: 16968948
[TBL] [Abstract][Full Text] [Related]
10. Lipoxins: putative braking signals in host defense, inflammation and hypersensitivity.
Brady HR; Serhan CN
Curr Opin Nephrol Hypertens; 1996 Jan; 5(1):20-7. PubMed ID: 8834158
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
12. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics.
Serhan CN; Chiang N
Rheum Dis Clin North Am; 2004 Feb; 30(1):69-95. PubMed ID: 15061569
[TBL] [Abstract][Full Text] [Related]
13. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
Vachier I; Bonnans C; Chavis C; Farce M; Godard P; Bousquet J; Chanez P
J Allergy Clin Immunol; 2005 Jan; 115(1):55-60. PubMed ID: 15637547
[TBL] [Abstract][Full Text] [Related]
14. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
Prasse A; Pechkovsky DV; Toews GB; Schäfer M; Eggeling S; Ludwig C; Germann M; Kollert F; Zissel G; Müller-Quernheim J
Arthritis Rheum; 2007 May; 56(5):1685-93. PubMed ID: 17469163
[TBL] [Abstract][Full Text] [Related]
15. [Lipoxins--new view on old mediators carrying potent anti-inflammatory action].
Jarmakowska K; Kuna P
Pol Merkur Lekarski; 2005 May; 18(107):491-5. PubMed ID: 16161940
[TBL] [Abstract][Full Text] [Related]
16. Lung involvement in systemic sclerosis.
Silver RM; Miller KS
Rheum Dis Clin North Am; 1990 Feb; 16(1):199-216. PubMed ID: 2406808
[TBL] [Abstract][Full Text] [Related]
17. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis.
Martins V; Valença SS; Farias-Filho FA; Molinaro R; Simões RL; Ferreira TP; e Silva PM; Hogaboam CM; Kunkel SL; Fierro IM; Canetti C; Benjamim CF
J Immunol; 2009 May; 182(9):5374-81. PubMed ID: 19380784
[TBL] [Abstract][Full Text] [Related]
18. The role of leukotrienes in alveolitis associated with scleroderma.
Simms RW; Korn JH
Arthritis Rheum; 2003 Jun; 48(6):1478-80. PubMed ID: 12794812
[No Abstract] [Full Text] [Related]
19. [Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis].
Savarino E; Ghio M; Marabotto E; Zentilin P; Sammito G; Cittadini G; Sconfienza L; Murolo C; Gemignani L; Indiveri F; Savarino V
Recenti Prog Med; 2009 Nov; 100(11):512-6. PubMed ID: 20066883
[TBL] [Abstract][Full Text] [Related]
20. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.
Izumo T; Kondo M; Nagai A
Life Sci; 2007 Apr; 80(20):1882-6. PubMed ID: 17397875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
